Retrospective Case-Cohort Study on Risk Factors for Developing Distant Metastases in Women With Breast Cancer

IF 3.1 2区 医学 Q2 ONCOLOGY
Cancer Medicine Pub Date : 2025-04-18 DOI:10.1002/cam4.70903
Serena Bertozzi, Ambrogio Pietro Londero, Giovanni Vendramelli, Maria Orsaria, Laura Mariuzzi, Enrico Pegolo, Carla Di Loreto, Carla Cedolini, Vincenzo Della Mea
{"title":"Retrospective Case-Cohort Study on Risk Factors for Developing Distant Metastases in Women With Breast Cancer","authors":"Serena Bertozzi,&nbsp;Ambrogio Pietro Londero,&nbsp;Giovanni Vendramelli,&nbsp;Maria Orsaria,&nbsp;Laura Mariuzzi,&nbsp;Enrico Pegolo,&nbsp;Carla Di Loreto,&nbsp;Carla Cedolini,&nbsp;Vincenzo Della Mea","doi":"10.1002/cam4.70903","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>This study aimed to identify risk factors associated with the development of metastases in breast cancer patients, to investigate survival rates, and the relationship between local recurrences and distant metastases.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective case-cohort study included women with breast cancer who were treated at a certified Breast Unit between 2001 and 2015. Cases who developed distant metastases were compared to controls based on diagnosis year, stage, and age at diagnosis. Comprehensive information on patient characteristics, tumor biology, and treatment options was gathered.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The study included 412 patients who developed distant metastases and 433 controls who remained metastasis-free over a median follow-up of 150 months (interquartile range 87–202). The 20-year overall survival was 99.23% for the control group and 23.62% for those with metastasis (<i>p</i> &lt; 0.01). Significant risk factors for metastasis included lobular invasive carcinoma (odds ratio (OR) 2.26, <i>p</i> &lt; 0.001), triple-negative subtype (OR 4.06, <i>p</i> = 0.002), high tumor grade (OR 2.62, <i>p</i> = 0.004), larger tumor size (OR 1.02, <i>p</i> &lt; 0.001), lymph node involvement (<i>p</i> &lt; 0.001), and loco-regional recurrence (OR 4.32, <i>p</i> &lt; 0.001). Progesterone receptor (PR) expression was protective (OR 0.52, 95% confidence interval 0.34–0.81, <i>p</i> = 0.003). Machine learning models supported these findings, though their clinical significance was limited.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Lobular invasive carcinoma, specific tumor subtypes, high grade, large tumor size, lymph node involvement, and loco-regional recurrence are all significant risk factors for distant metastasis, whereas PR expression is protective. The potential of machine learning in predicting metastasis was explored, showing promise for future personalized risk assessment.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"14 8","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.70903","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.70903","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

This study aimed to identify risk factors associated with the development of metastases in breast cancer patients, to investigate survival rates, and the relationship between local recurrences and distant metastases.

Methods

This retrospective case-cohort study included women with breast cancer who were treated at a certified Breast Unit between 2001 and 2015. Cases who developed distant metastases were compared to controls based on diagnosis year, stage, and age at diagnosis. Comprehensive information on patient characteristics, tumor biology, and treatment options was gathered.

Results

The study included 412 patients who developed distant metastases and 433 controls who remained metastasis-free over a median follow-up of 150 months (interquartile range 87–202). The 20-year overall survival was 99.23% for the control group and 23.62% for those with metastasis (p < 0.01). Significant risk factors for metastasis included lobular invasive carcinoma (odds ratio (OR) 2.26, p < 0.001), triple-negative subtype (OR 4.06, p = 0.002), high tumor grade (OR 2.62, p = 0.004), larger tumor size (OR 1.02, p < 0.001), lymph node involvement (p < 0.001), and loco-regional recurrence (OR 4.32, p < 0.001). Progesterone receptor (PR) expression was protective (OR 0.52, 95% confidence interval 0.34–0.81, p = 0.003). Machine learning models supported these findings, though their clinical significance was limited.

Conclusions

Lobular invasive carcinoma, specific tumor subtypes, high grade, large tumor size, lymph node involvement, and loco-regional recurrence are all significant risk factors for distant metastasis, whereas PR expression is protective. The potential of machine learning in predicting metastasis was explored, showing promise for future personalized risk assessment.

Abstract Image

乳腺癌妇女远处转移危险因素的回顾性病例队列研究
目的探讨乳腺癌患者发生转移的相关危险因素,探讨乳腺癌患者的生存率以及局部复发与远处转移的关系。方法:本回顾性病例队列研究纳入了2001年至2015年间在一家认证的乳腺部门接受治疗的乳腺癌妇女。根据诊断年份、分期和诊断年龄,将发生远处转移的病例与对照组进行比较。收集了有关患者特征、肿瘤生物学和治疗方案的综合信息。该研究包括412例远处转移患者和433例未发生转移的对照组,中位随访时间为150个月(四分位数范围87-202)。对照组20年总生存率为99.23%,转移组20年总生存率为23.62% (p < 0.01)。发生转移的重要危险因素包括小叶浸润性癌(比值比(OR) 2.26, p < 0.001)、三阴性亚型(OR 4.06, p = 0.002)、高肿瘤分级(OR 2.62, p = 0.004)、较大肿瘤大小(OR 1.02, p < 0.001)、淋巴结累及(p < 0.001)和局部区域复发(OR 4.32, p < 0.001)。孕激素受体(PR)的表达具有保护作用(OR 0.52, 95%可信区间0.34 ~ 0.81,p = 0.003)。机器学习模型支持这些发现,尽管它们的临床意义有限。结论小叶浸润性癌、特异性肿瘤亚型、肿瘤分级高、肿瘤体积大、淋巴结受损伤、局部区域复发均是发生远处转移的重要危险因素,而PR表达具有保护作用。研究人员探索了机器学习在预测转移中的潜力,为未来的个性化风险评估带来了希望。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cancer Medicine
Cancer Medicine ONCOLOGY-
CiteScore
5.50
自引率
2.50%
发文量
907
审稿时长
19 weeks
期刊介绍: Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信